Home > Insider Trading > Filing (0001209191-21-007638)

Filing Details

Accession Number:: 0001209191-21-007638
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-03 21:39:39
Reporting Period:: 2021-02-01

Accepted Time:: 2021-02-03 21:39:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1563584	M John Leonard	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-02-01	100,000	$6.83	575,488	No	4	M	Direct
Common Stock	Disposition	2021-02-01	16,750	$63.32	558,738	No	4	S	Direct
Common Stock	Disposition	2021-02-01	26,058	$64.13	532,680	No	4	S	Direct
Common Stock	Disposition	2021-02-01	8,827	$65.00	523,853	No	4	S	Direct
Common Stock	Acquisiton	2021-02-01	10,000	$13.88	533,853	No	4	M	Direct
Common Stock	Disposition	2021-02-01	1,709	$63.24	532,144	No	4	S	Direct
Common Stock	Disposition	2021-02-01	3,497	$64.16	528,647	No	4	S	Direct
Common Stock	Disposition	2021-02-01	693	$65.02	527,954	No	4	S	Direct
Common Stock	Acquisiton	2021-02-01	30,000	$18.30	557,954	No	4	M	Direct
Common Stock	Disposition	2021-02-01	6,448	$63.29	551,506	No	4	S	Direct
Common Stock	Disposition	2021-02-01	9,432	$64.09	542,074	No	4	S	Direct
Common Stock	Disposition	2021-02-01	3,260	$65.03	538,814	No	4	S	Direct
Common Stock	Acquisiton	2021-02-01	60,000	$22.78	598,814	No	4	M	Direct
Common Stock	Disposition	2021-02-01	11,100	$63.30	587,714	No	4	S	Direct
Common Stock	Disposition	2021-02-01	16,640	$64.10	571,074	No	4	S	Direct
Common Stock	Disposition	2021-02-01	5,475	$65.04	565,599	No	4	S	Direct
Common Stock	Acquisiton	2021-02-03	50,000	$22.78	615,599	No	4	M	Direct
Common Stock	Disposition	2021-02-03	30,998	$72.00	584,601	No	4	S	Direct
Common Stock	Acquisiton	2021-02-03	67,060	$13.88	651,661	No	4	M	Direct
Common Stock	Disposition	2021-02-03	36,858	$73.00	614,803	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-02-01	100,000	$0.00	100,000	$6.83
Common Stock	Stock Option (right to buy)	Disposition	2021-02-01	10,000	$0.00	10,000	$13.88
Common Stock	Stock Option (right to buy)	Disposition	2021-02-01	30,000	$0.00	30,000	$18.30
Common Stock	Stock Option (right to buy)	Disposition	2021-02-01	60,000	$0.00	60,000	$22.78
Common Stock	Stock Option (right to buy)	Disposition	2021-02-03	50,000	$0.00	50,000	$22.78
Common Stock	Stock Option (right to buy)	Disposition	2021-02-03	67,060	$0.00	67,060	$13.88

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,234	2026-02-02	No	4	M	Direct
85,000	2027-01-05	No	4	M	Direct
27,500	2027-12-11	No	4	M	Direct
160,000	2028-01-24	No	4	M	Direct
110,000	2028-01-24	No	4	M	Direct
17,940	2027-01-05	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	58,415	Indirect	By Trust

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.685, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.70 to $65.48, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.74 to $63.545, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.865 to $65.09, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.68 to $63.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.70 to $65.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
Shares held by the John M. Leonard 2015 Irrevocable Trust.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 55,885 shares as of February 1, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 95,000 shares as of February 1, 2021.